Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BEAM Followed By ASCT For Relapsed B-Cell Non-Hodgkin Lymphoma
Status:
Completed
Trial end date:
2017-03-27
Target enrollment:
Participant gender:
Summary
This phase II clinical trial studies how well yttrium Y 90 ibritumomab tiuxetan, rituximab,
and high-dose chemotherapy followed by peripheral blood stem cell transplant in treating
patients with relapsed B-cell non-Hodgkin lymphoma. Monoclonal antibodies, such as yttrium Y
90 ibritumomab tiuxetan and rituximab, can block cancer growth in different ways. Some block
the ability of cancer cells to grow and spread. Others find cancer cells and help kill them
or carry cancer-killing substances to them. Radiolabeled monoclonal antibodies can find tumor
cells and carry tumor-killing substances to them without harming normal cells. Giving
monoclonal antibody therapy, radioimmunotherapy (RIT), and high-dose combination chemotherapy
before a peripheral blood stem cell transplant may be an effective treatment for non-Hodgkin
lymphoma.